Literature DB >> 17496813

Increased immunoreactivity of cdk5 activators in hippocampal sclerosis.

Arjune Sen1, Maria Thom, Lillian Martinian, Mahinda Yogarajah, Margareta Nikolic, Sanjay M Sisodiya.   

Abstract

Cyclin-dependent kinase 5 is important in several in-vitro neurodegeneration paradigms. Whether cyclin-dependent kinase 5 contributes to cell death in human neurodegenerative diseases remains uncertain, particularly because post-mortem delay and other extrinsic factors might influence cyclin-dependent kinase 5 activity. Here we demonstrate increased immunoreactivity for the activators of cyclin-dependent kinase 5 in post-mortem human hippocampi affected by the neurodegenerative condition hippocampal sclerosis, but not in histologically normal hippocampi. Moreover, in post-mortem brain tissue from patients with unilateral hippocampal sclerosis, increased immunoreactivity for cyclin-dependent kinase 5 activators was detected in the hippocampus with sclerosis, but not in the contralateral hippocampus, suggesting that extrinsic factors are unlikely to account for the differential staining observed. Our findings suggest that deregulation of cyclin-dependent kinase 5 might contribute to the pathogenesis of hippocampal sclerosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17496813     DOI: 10.1097/WNR.0b013e3280586879

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  5 in total

1.  Neurodegeneration and neuroinflammation in cdk5/p25-inducible mice: a model for hippocampal sclerosis and neocortical degeneration.

Authors:  David Muyllaert; Dick Terwel; Anna Kremer; Kristina Sennvik; Peter Borghgraef; Herman Devijver; Ilse Dewachter; Fred Van Leuven
Journal:  Am J Pathol       Date:  2008-01-17       Impact factor: 4.307

2.  Neurofibrillary tangle pathology and Braak staging in chronic epilepsy in relation to traumatic brain injury and hippocampal sclerosis: a post-mortem study.

Authors:  Maria Thom; Joan Y W Liu; Pam Thompson; Rahul Phadke; Marta Narkiewicz; Lillian Martinian; Derek Marsdon; Matthias Koepp; Luis Caboclo; Claudia B Catarino; Sanjay M Sisodiya
Journal:  Brain       Date:  2011-09-08       Impact factor: 13.501

Review 3.  Cognition and dementia in older patients with epilepsy.

Authors:  Arjune Sen; Valentina Capelli; Masud Husain
Journal:  Brain       Date:  2018-06-01       Impact factor: 13.501

4.  Regulation of hippocampal and behavioral excitability by cyclin-dependent kinase 5.

Authors:  Ammar H Hawasli; Della Koovakkattu; Kanehiro Hayashi; Anne E Anderson; Craig M Powell; Christopher M Sinton; James A Bibb; Donald C Cooper
Journal:  PLoS One       Date:  2009-06-04       Impact factor: 3.240

5.  An Investigation of Levetiracetam in Alzheimer's Disease (ILiAD): a double-blind, placebo-controlled, randomised crossover proof of concept study.

Authors:  Arjune Sen; Mary Akinola; Xin You Tai; Mkael Symmonds; Gabriel Davis Jones; Sergio Mura; Joanne Galloway; Angela Hallam; Jane Y C Chan; Ivan Koychev; Chris Butler; John Geddes; Rohan Van Der Putt; Sian Thompson; Sanjay G Manohar; Eleni Frangou; Sharon Love; Rupert McShane; Masud Husain
Journal:  Trials       Date:  2021-07-31       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.